Regulation of spontaneous glutamate release activity in osteoblastic cells and its role in differentiation and survival: evidence for intrinsic glutamatergic signaling in bone
Authors:
- 9 May 2001
- journal article
- Published by Wiley in The FASEB Journal
- Vol. 15 (9) , 1586-1588
Abstract
Maintenance of bone mass depends on numerous osteoblast‐derived autocrine and paracrine signaling factors that ensure the coupled resorptive and formative activity of osteoclasts and osteoblasts. Here, we provide the first evidence that osteoblasts actively secrete glutamate, an amino acid neurotransmitter found at excitatory synapses in the central nervous system, complementing previous reports of functional glutamate receptor expression by bone cells. Several osteoblastic cell‐types spontaneously released between 2–7 nmoles glutamate per mg protein, equivalent to or greater than reported levels of glutamate release from depolarized neurons. Osteoblastic glutamate exocytosis appeared dependent on an AMPA‐type glutamate autoreceptor, and addition of depolarizing concentrations of KCl caused significant calcium‐dependent inhibition of glutamate release. Levels of exocytosed and intracellular free glutamate, and susceptibility to depolarization‐induced inhibition of glutamate release, increased during osteoblastic differentiation of MC3T3‐E1 cells. Pharmacological inhibition of glutamate release with riluzole (1–25 µM) significantly inhibited differentiation and induced morphological and biochemical characteristics of apoptosis in osteoblastic cells. Exogenous glutamate application increased survival rates of osteoblasts grown in serum‐free medium, and proinflammatory cytokines (tumor necrosis factor–α and interferon–γ) significantly inhibited osteoblastic glutamate release. These findings provide evidence for an intrinsic synaptic‐like glutamatergic signaling network in bone that is essential for in vitro osteoblast differentiation and survival.Keywords
This publication has 38 references indexed in Scilit:
- Specific Antagonists of NMDA Receptors Prevent Osteoclast Sealing Zone Formation Required for Bone ResorptionBiochemical and Biophysical Research Communications, 2000
- The glutamate receptor antagonist MK801 modulates bone resorption in vitro by a mechanism predominantly involving osteoclast differentiationThe FASEB Journal, 1999
- Functional characterization of N-methyl-d-aspartic acid-gated channels in bone cellsBone, 1999
- Active NMDA glutamate receptors are expressed by mammalian osteoclastsThe Journal of Physiology, 1999
- Expression of an N-Methyl-D-Aspartate-Type Receptor by Human and Rat Osteoblasts and Osteoclasts Suggests a Novel Glutamate Signaling Pathway in BoneBone, 1998
- Osteoblast Programmed Cell Death (Apoptosis): Modulation by Growth Factors and CytokinesJournal of Bone and Mineral Research, 1998
- Glutamate Receptors Are Expressed by Bone Cells and Are Involved in Bone ResorptionBone, 1998
- Apoptosis during bone-like tissue development in vitroJournal of Cellular Biochemistry, 1998
- Mechanically regulated expression of a neural glutamate transporter in bone: A role for excitatory amino acids as osteotropic agents?Bone, 1997
- The synaptic vesicle cycle: a cascade of protein–protein interactionsNature, 1995